Telavancin News
Most Popular Telavancin Story
Drug work completed, Theravance cuts 40% of staff
Theravance announced that it is cutting 40 percent of its workforce now that it has finished work on its antibiotic telavancin. Telavancin is currently undergoing FDA review: in March the FDA... Read more...
Latest Headlines
- January 29, 2010
- November 30, 2009
- October 23, 2009
- September 14, 2009
- February 27, 2009
- November 20, 2008
- November 17, 2008
- April 23, 2008
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
